Figure 1.

Correlation between fatigue levels and cerebral flow after 12 weeks of treatment with adalimumab. (a) Grey matter (P = 0.005). (b) White matter (P = 0.014). FACIT, functional assessment of chronic illness therapy fatigue scale.